WO2000053148A3 - Methods and compositions for treating erectile dysfunction - Google Patents

Methods and compositions for treating erectile dysfunction Download PDF

Info

Publication number
WO2000053148A3
WO2000053148A3 PCT/US2000/005711 US0005711W WO0053148A3 WO 2000053148 A3 WO2000053148 A3 WO 2000053148A3 US 0005711 W US0005711 W US 0005711W WO 0053148 A3 WO0053148 A3 WO 0053148A3
Authority
WO
WIPO (PCT)
Prior art keywords
erectile dysfunction
methods
present
compositions
treating erectile
Prior art date
Application number
PCT/US2000/005711
Other languages
French (fr)
Other versions
WO2000053148A2 (en
Inventor
Elizabeth Stoner
Original Assignee
Merck & Co Inc
Waldstreicher Joanne
Elizabeth Stoner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Waldstreicher Joanne, Elizabeth Stoner filed Critical Merck & Co Inc
Priority to CA002362918A priority Critical patent/CA2362918A1/en
Priority to EP00916081A priority patent/EP1161255A4/en
Priority to AU37244/00A priority patent/AU3724400A/en
Publication of WO2000053148A2 publication Critical patent/WO2000053148A2/en
Publication of WO2000053148A3 publication Critical patent/WO2000053148A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Abstract

The present invention provides for a method for the treatment of erectile dysfunction in a male or female human subject in need of such treatment comprising administration of a therapeutically effective amount of an agonist of the melanocortin receptor in combination with a therapeutically effective amount of a cyclic-GMP-specific phosphodiesterase inhibitor or an alpha-adrenergic receptor antagonist. Further, the present invention provides for pharmaceutical compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating erectile dysfunction.
PCT/US2000/005711 1999-03-08 2000-03-03 Methods and compositions for treating erectile dysfunction WO2000053148A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002362918A CA2362918A1 (en) 1999-03-08 2000-03-03 Methods and compositions for treating erectile dysfunction
EP00916081A EP1161255A4 (en) 1999-03-08 2000-03-03 Methods and compositions for treating erectile dysfunction
AU37244/00A AU3724400A (en) 1999-03-08 2000-03-03 Methods and compositions for treating erectile dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12324499P 1999-03-08 1999-03-08
US60/123,244 1999-03-08

Publications (2)

Publication Number Publication Date
WO2000053148A2 WO2000053148A2 (en) 2000-09-14
WO2000053148A3 true WO2000053148A3 (en) 2000-12-14

Family

ID=22407530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005711 WO2000053148A2 (en) 1999-03-08 2000-03-03 Methods and compositions for treating erectile dysfunction

Country Status (4)

Country Link
EP (1) EP1161255A4 (en)
AU (1) AU3724400A (en)
CA (1) CA2362918A1 (en)
WO (1) WO2000053148A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
NO20002097L (en) * 1999-04-30 2001-10-26 Lilly Icos Llc Preparation items
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
ATE399554T1 (en) 1999-08-03 2008-07-15 Lilly Icos Llc PHARMACEUTICAL COMPOSITION CONTAINING TADALAFIL
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
JP4336196B2 (en) * 2001-07-18 2009-09-30 メルク エンド カムパニー インコーポレーテッド Crosslinked piperidine derivatives as melanocortin receptor agonists
BR0305628A (en) 2002-07-09 2004-09-08 Palatin Technologies Inc Pharmaceutical composition for treating sexual dysfunction in a mammal comprising peptide and its use

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028902A1 (en) * 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones for the treatment of impotence
WO1996016657A1 (en) * 1994-11-26 1996-06-06 Pfizer Limited Bicyclic heterocyclic compounds for the treatment of impotence
US5567706A (en) * 1993-02-10 1996-10-22 Gavras; Haralambos Method for treating impotence
US5576290A (en) * 1993-04-05 1996-11-19 Competitive Technologies, Inc. Compositions and methods for the diagnosis and treatment of psychogenic erectile dysfunction
WO1997003675A1 (en) * 1995-07-14 1997-02-06 Icos Corporation Use of cgmp-phosphodiesterase inhibitors to treat impotence
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1999030718A2 (en) * 1997-12-18 1999-06-24 Nathan Earl Scott PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL
WO1999030697A2 (en) * 1997-12-16 1999-06-24 Pfizer Products Inc. Combination effective for the treatment of impotence
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
EP0960621A2 (en) * 1998-05-15 1999-12-01 Pfizer Inc. Pharmaceutical formulations comprising sildenafil
WO1999060985A2 (en) * 1998-05-26 1999-12-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
WO1999066933A1 (en) * 1998-06-25 1999-12-29 New Millennium Pharmaceutical Research, Inc. Nasal administration of sildenafil for the treatment of erectile dysfunction
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5567706A (en) * 1993-02-10 1996-10-22 Gavras; Haralambos Method for treating impotence
US5576290A (en) * 1993-04-05 1996-11-19 Competitive Technologies, Inc. Compositions and methods for the diagnosis and treatment of psychogenic erectile dysfunction
US6051555A (en) * 1993-04-05 2000-04-18 Hadley; Mac E. Stimulating sexual response in females
WO1994028902A1 (en) * 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones for the treatment of impotence
WO1996016657A1 (en) * 1994-11-26 1996-06-06 Pfizer Limited Bicyclic heterocyclic compounds for the treatment of impotence
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1997003675A1 (en) * 1995-07-14 1997-02-06 Icos Corporation Use of cgmp-phosphodiesterase inhibitors to treat impotence
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO1999030697A2 (en) * 1997-12-16 1999-06-24 Pfizer Products Inc. Combination effective for the treatment of impotence
WO1999030718A2 (en) * 1997-12-18 1999-06-24 Nathan Earl Scott PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL
EP0960621A2 (en) * 1998-05-15 1999-12-01 Pfizer Inc. Pharmaceutical formulations comprising sildenafil
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
WO1999060985A2 (en) * 1998-05-26 1999-12-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
WO1999066933A1 (en) * 1998-06-25 1999-12-29 New Millennium Pharmaceutical Research, Inc. Nasal administration of sildenafil for the treatment of erectile dysfunction
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1161255A4 *

Also Published As

Publication number Publication date
EP1161255A2 (en) 2001-12-12
AU3724400A (en) 2000-09-28
CA2362918A1 (en) 2000-09-14
WO2000053148A2 (en) 2000-09-14
EP1161255A4 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2005107726A3 (en) Method for the treatment of back pain
NO993520D0 (en) Dosage forms and methods for improving erectile dysfunction
DE60038290D1 (en) OPIOIDANT AGONIC COMPOSITION FOR INCREASING THE ANALGETIC EFFICACY OF TRAMADOL AND REDUCING THEIR SIDE EFFECTS
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
WO2004005324A3 (en) Peptide composition for treatment of sexual dysfunction
EP1149579A3 (en) Use of an estrogen agonist/antagonist for treating female sexual dysfunction
WO2004055010A3 (en) Cyclopropyl compounds as ccr5 antagonists
WO2002099388A3 (en) Benzodiazepine bradykinin antagonists
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
AU5895496A (en) Phenyldihydrobenzofurans
WO2006049933A3 (en) Compositions and methods for the treatment of obesity and sexual dysfunction
WO2002070524A3 (en) N-but-3-enyl norbuprenorphine and its use as analgesic
WO2006047392A3 (en) Nicotinic-opioid synergy for analgesia
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
EP1415652A3 (en) Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction
BG105664A (en) Use of apomophines for the treatment of organic erectile dysfunction in males
AU5764496A (en) Cyclohexyl dihydrobenzofuranes
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2005011590A3 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
HUP0402358A2 (en) Use of selective dopamine d4 receptor agonists for preparation of pharmaceutical composition for treating sexual dysfunction
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 37244/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2362918

Country of ref document: CA

Ref document number: 2362918

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000916081

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 603637

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000916081

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916081

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)